Predictive Oncology INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Axe Compute Inc. officer Joshua Blacher reports a transaction involving restricted stock units.
Director Theodore Zhu acquired 5,144 shares of Axe Compute Inc. common stock as compensation for board service.
Axe Compute Inc. director Charles Lee Nuzum Sr. acquired 14,082 shares of common stock as compensation for board services.
Axe Compute Inc. Director Veena Rao received 4,197 shares of common stock as compensation for board services on March 6, 2026.
Axe Compute Inc. director Shawn Matthews was issued 1,166 shares of common stock as compensation for his board service.
Director Gregory St. Clair Sr. acquired 9,419 shares of Axe Compute Inc. as compensation for board service, increasing his total holdings to 15,146 shares.
Director Matthew Hawryluk acquired 6,782 shares of Axe Compute Inc. as compensation for board service, increasing his total direct ownership to 11,727 shares.
Director Daniel Handley acquired 5,663 shares of Axe Compute Inc. as compensation for board service, bringing his total ownership to 11,040 shares.
Axe Compute Inc. reports the grant of 225,000 stock options to Co-Chief Financial Officer Jeremy Yaukey-Witter as an inducement award.
Axe Compute Inc. reports the grant of 300,000 non-qualified stock options to President Kyle Robert Okamoto.
Axe Compute Inc. CEO Raymond F Vennare's employment was terminated, coinciding with recent RSU transactions and tax withholdings.
Predictive Oncology Inc. CEO Raymond F Vennare reported a disposition of 2,373 common shares withheld for tax purposes following the vesting of restricted stock units.
Predictive Oncology Inc. Director Nancy Chung-Welch was granted 64,680 restricted stock units, vesting fully on October 31, 2025.
Predictive Oncology Inc. Director Daniel E. Handley received a grant of 64,680 restricted stock units, which are set to vest on October 31, 2025.
Predictive Oncology Inc. Director Matthew Hawryluk was granted 64,680 restricted stock units, vesting fully on October 31, 2025.
Predictive Oncology Inc. Director Veena Rao was granted 64,680 restricted stock units, vesting in full on October 31, 2025.
Predictive Oncology Inc. Director Gregory St. Clair received a grant of 64,680 restricted stock units, vesting fully on October 31, 2025.
Predictive Oncology Inc. Director Charles Lee Nuzum Sr. was granted 64,680 restricted stock units, vesting October 31, 2025.
Predictive Oncology's Interim CFO, Joshua Blacher, was granted 97,000 restricted stock units, which are scheduled to vest on October 31, 2025.
Predictive Oncology Inc.'s CEO, Raymond F. Vennare, was granted 124,959 restricted stock units, vesting fully on October 31, 2025.
Predictive Oncology and Renovaro extend their merger agreement termination date to March 31, 2025, with Renovaro providing initial financing to integrate AI/ML platforms and expand business development.
Gregory St. Clair Sr., a director of Predictive Oncology Inc., acquired 3,268 shares of common stock on April 5, 2024.
Director Matthew Hawryluk of Predictive Oncology Inc. reports acquiring and disposing of common stock on April 5, 2024.
Director Veena Rao of Predictive Oncology Inc. reports acquiring and disposing of common stock on April 5, 2024.
Director Charles Lee Nuzum Sr. reports acquiring 3,268 shares of Predictive Oncology Inc. common stock on April 5, 2024.
Director Daniel E. Handley reports acquiring and disposing of shares of Predictive Oncology Inc. on April 5, 2024.
Director Nancy Chung-Welch reports acquiring and disposing of Predictive Oncology Inc. (POAI) common stock on April 5, 2024.